What does a speedometer and the costs of drugs have in common, not much right, wrong, it’s all about the patents. The Supreme Court is scheduled to hear arguments in the case of Cuozzo Speed Technologies, LLC v. Lee, which is challenging the new procedure – called inter partes review for patent challenges.
When someone challenges a patent in the court, patents are presumed to be valid and understood by their “plain and ordinary meaning” but with the new procedure a more broad interpretation is applied; to drug makers this is problem. Per Pharmaceutical Researchers and Manufacturers of America, it costs an average of $2.6 billion to develop a new drug; patent protection is required to justify that investment. Read article here….
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.